Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.24 +2.5%	$1.37	$1.05 ▼ $10.16	$38.88M	1.55	255,109 shs	283,795 shs
BRNS Barinthus Biotherapeutics	$0.89 +1.6%	$0.89	$0.64 ▼ $1.65	$35.10M	-0.78	36,710 shs	10,861 shs
ELYM Eliem Therapeutics	$1.23 +2.5%	$1.26	$2.35 ▼ $11.55	$36.60M	-0.39	486,688 shs	283,275 shs
IMV IMV		$0.66	$0.48 ▼ $12.70	$9.63M	0.95	233,607 shs	44,800 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.48%	-2.36%	+5.08%	-75.88%	-81.30%
BRNS Barinthus Biotherapeutics	+1.59%	-9.15%	+5.18%	-11.49%	-44.81%
ELYM Eliem Therapeutics	-5.51%	-12.41%	-6.98%	-11.11%	-83.67%
IMV IMV	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	4.1153 of 5 stars	4.5	5.0	0.0	0.0	2.0	3.3	0.6
BRNS Barinthus Biotherapeutics	2.0897 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.8	1.3
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,328.57% Upside
BRNS Barinthus Biotherapeutics	3.00	Buy	$6.25	599.11% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
IMV IMV	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMV, BRNS, ELYM, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/24/2025	BRNS Barinthus Biotherapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/21/2025	BRNS Barinthus Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	2.41	N/A	N/A	$3.23 per share	0.28
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
IMV IMV	$330K	0.00	N/A	N/A	($0.69) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.64	N/A	N/A	N/A	N/A	-46.43%	-38.50%	8/6/2025 (Estimated)
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
IMV IMV	-$37.99M	-$4.59	N/A	N/A	N/A	-11,547.42%	-12,695.41%	-104.84%	N/A

Latest IMV, BRNS, ELYM, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/7/2025	Q1 2025	BRNS Barinthus Biotherapeutics	-$0.34	-$0.49	-$0.15	-$0.49	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/20/2025	Q4 2024	BRNS Barinthus Biotherapeutics	-$0.50	-$0.51	-$0.01	-$0.51	N/A	$14.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
BRNS Barinthus Biotherapeutics	N/A	9.18	9.18
ELYM Eliem Therapeutics	N/A	60.41	60.41
IMV IMV	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
BRNS Barinthus Biotherapeutics	25.20%
ELYM Eliem Therapeutics	69.76%
IMV IMV	15.37%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
BRNS Barinthus Biotherapeutics	10.70%
ELYM Eliem Therapeutics	4.70%
IMV IMV	0.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
IMV IMV	97	11.71 million	11.67 million	Optionable

IMV, BRNS, ELYM, and ACRV Headlines

Recent News About These Companies

Maryland announces $1.25 million in grants for development around rail stations

June 11, 2025 | thebaltimorebanner.com

Is This The Next Toyota FJ Cruiser?

June 1, 2025 | msn.com

BioVaxys and Horizon Technology Finance Corp. execute amendment to asset purchase agreement

May 30, 2025 | canadianmanufacturing.com

New IMV Study Reveals Key Trends in U.S. Breast Imaging: Procedure Growth, Equipment Plans, and Patient Priorities

May 30, 2025 | finance.yahoo.com

Everything To Know About Toyota's $13,000 Pickup Truck

May 21, 2025 | msn.com

Toyota's Land Cruiser FJ Set to Redefine Compact Off-Roading with a 2026 Debut

May 19, 2025 | msn.com

Red Wings

May 14, 2025 | bleacherreport.com

Deep Learning Boosts CT Diagnosis of Heart Ischaemia

May 2, 2025 | emjreviews.com

Americans Claim They Really Want a $10K Truck With No Safety Features

April 27, 2025 | msn.com

CT Scans May Cause as Many as 5% of Cancers Diagnosed Each Year in the US

April 16, 2025 | cancertherapyadvisor.com

Mangaluru city police book 489 cases against buses in special drive

March 27, 2025 | timesofindia.indiatimes.com

Treatment Outcomes of Anticoagulation and Steroids in COVID 19

February 13, 2025 | physiciansweekly.com

Social security suspends the minimum vital income from families due to management delays

February 6, 2025 | newslite.tv

Mechanical Ventilation Elevates AKI Risk in ICU

February 4, 2025 | emjreviews.com

We imagine what the new Toyota Hilux could look like

January 23, 2025 | topgear.com.ph

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome

January 17, 2025 | pharmabiz.com

2026 Toyota HiLux: Everything we know so far

January 10, 2025 | whichcar.com.au

Study identifies genetic cause for yellow nail syndrome

December 24, 2024 | eurekalert.org

BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

December 17, 2024 | finance.yahoo.com

Toyota Hilux Rangga SUV To Launch On IMV Platform Like Fortuner, Innova Crysta

December 17, 2024 | rushlane.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMV, BRNS, ELYM, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.24 +0.03 (+2.48%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.02 (+1.94%)

As of 06/18/2025 07:28 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.89 +0.01 (+1.59%)

Closing price 06/18/2025 03:52 PM Eastern

Extended Trading

$0.91 +0.02 (+2.01%)

As of 06/18/2025 07:40 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Eliem Therapeutics NASDAQ:ELYM

$1.23 +0.03 (+2.50%)

As of 06/18/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

IMV NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time